Xie Lu presenting thr PRESIDENTIAL SYMPOSIUM of the Ris-Rez RP3 study for advanced osteosarcoma! @myESMO #ESMO26

With the typoon gone, now I am finally able to move to @myESMO #ESMO26. Although it's a short run, I definitely still hope to meet everyone, greet, learn and chat!😍

📢Presidential Symposium III at #ESMO26 Unprecedented results in osteosarcoma, promising data in gynaecological cancers, reflections on immune checkpoint inhibitors. ow.ly/HwRO50ZYRIc @AndresC27622123 @LizzySmyth1

Nuclear grading of myxoid liposarcoma demonstrates superior prognostic performance over conventional grading, which is traditionally based on the proportion of the round cell component. Read Marcelis L … Folpe AL doi.org/10.1007/s00428-026-0…

Leveraging Real-World Evidence to Drive Advances in Oncology Care in the Asia-Pacific Region: Recommendations from the APODDC Working Group. Co-authored by @herbloong. Read the full article. bit.ly/3U2r3Qo

Are we asking oncology professionals to become more resilient, when we should also be asking how to make our systems less exhausting? Resilience isn’t just about individual coping. It’s also about the environments we work in, the support we receive, and how we sustain meaning and motivation throughout our careers. At #ESMO26, on behalf of ESMOs Resilience Taskforce we’re bringing together different perspectives on this important conversation: 🔹 Launching the ESMO Resilience Resource Hub 🔹 Understanding imposter syndrome, cognitive distortions & professional identity 🔹 Moving beyond self-care towards practical, trainable coping skills 🔹 Exploring how we can design systems that strengthen resilience across the oncology profession I’m delighted to co-chair this special session with @BanerjeeSusana and share my perspective on moving from individual coping to systemic change. 💬 Come ready to share your experiences, challenge assumptions and help shape the conversation! 📅 Sunday 25 October | 10:15–11:15 📍 Toledo Auditorium, NCC, Madrid ⚠️ In-person only — NOT livestreamed or recorded. We’d love to see you there! @ESMO #ESMORTF #ESMO26 @DrJonLim @DrVilmaPBarcia @ErulEnes

📢 Just published 💃 in @JCOGO_ASCO: the @APODDC Working Group’s recommendations on using real-world evidence (RWE) to advance oncology drug development across Asia-Pacific. Why this matters for APAC: 🌏 Pivotal trials often don’t reflect our patients. #Ethnicity, #tumourbiology, #comorbidities, #access and treatment patterns vary hugely across the region. 📋 Only 🇨🇳 China, 🇯🇵 Japan and 🇹🇼 Taiwan currently have formal RWE regulatory guidance. ⏳ In many #APAC systems, reimbursement lags regulatory approval by years. That window is an opportunity for local #RWD to show whether trial benefits hold up in our own health systems. 💊 RWE can support #label_extensions, #external_controls for #rare and #biomarker_defined cancers, #postmarketing safety and HTA, as a complement to RCTs. Key recommendations: ✅ Harmonised data standards and quality assurance ✅ Risk-proportionate governance, with federated analyses where data can’t cross borders ✅ Sustainable funding for registries and the people who run them ✅ A tiered infrastructure model so resource-limited centres can start small ✅ Transparent public–private partnerships and capacity building A truly international effort 🌐 with the entire @apoddc team including co-authors @pankajpanda86 @DrBenTran @ToshioShim1025 #PJVoon @fredtingmd #TakafumiKoyama #DaphneDay #KArnoldChan @wonglaihung and @danieltanmd Open access 👇 doi.org/10.1200/GO-26-00217 #RWE #RealWorldEvidence #DrugDevelopment #AsiaPacific #Oncology @APCLC_2023 @CUHKMedicine #globaloncology

ADC drug development is accelerating. But is biomarker science keeping pace? Nearly 50% of ADC trials require no biomarker, while most that do still rely on conventional IHC. In our new @NatRevClinOncol review published just in time pre-#ESMO26, we propose a modular framework to bridge this gap - moving beyond target expression to the multiple biological determinants of ADC efficacy and toxicity. Proud to lead this international effort with @BarbaraPistill2 @nedmcnamee @rreddel @VivekSubbiah and colleagues. 🔗: nature.com/articles/s41571-0…

【ATLAS Board Meeting】 The ATLAS Board Online Meeting was held on 29 September. Board members discussed the project’s future direction and upcoming activities, reaffirming their commitment to advancing the ATLAS Project through continued collaboration.

Well done #PDG4 at @MOGA_ORG @myESMO #ACORD26 workshop! Congrats on successfully putting your clinical research protocol together. Looking forward to seeing your projects come to fruition 😁 #drugdevelopment @AACR @ASCO

Good academic–industry collaboration isn’t “I have an idea; please fund it.” It starts with a clinically meaningful question ➡️ brings the right methodological team in early ➡️ understands what each partner needs ➡️ establishes feasibility/resources/governance before commitment Success ultimately depends on communication and trust. @ACORDISM @MartinStockler @oncodocsydney @herbloong @do_phd @batraatulonc

#ACORD26 off to a flying start! Thanks @myESMO @AACR @ASCO @CancerAustralia and many other sponsors for support! @oncodocsydney @MOGA_ORG @ACORDISM

ESMO Sarcoma and Rare Cancers 2027: Your findings today could shape tomo... piped.video/tCCvblSuE6U?si=ADKI… via @YouTube

ESMO's new Clinical Trials Funding initiative supports independent academic pragmatic clinical trials to improve #CancerCare and patient outcomes. Open to academic institutions, hospitals, research groups. Application deadline: 1 November 2026 ow.ly/482Q50ZLX3p

It's my great pleasure to be back at #ACORD26as a faculty member to help the attendees in Asia develop clinical trials in the coming weeks. Excited to see everyone soon.

We are delighted to bring you the CTOS Fall 2026 Webinar "Rhabdomyosarcoma- Sarcoma of the Year". We are looking forward to see all of you on Tuesday, September 22nd; 9am-11:30am EST! But first, register on our website: lnkd.in/eZ8K4QcB

1/ My first paper in PGY2 residency landed in JAMA Oncology, and the truth is it was won before I ran a single analysis. It came down to how I chose the question. 8 Years later, I realized that very few trainees got taught about how to pick a first research idea. Lets try a bit

Recent @Nature analysis shows the breakdown of cancer-related publications in the and reveals the cancer types with the highest output, and the leaders of the field. 📊 Breast cancer remains the most-studied cancer globally in the Nature Index (2021–2025), well ahead of lung cancer. 🌍 The 🇺🇸 and 🇨🇳 together contribute ~60% of global cancer research output in the Nature Index. 🏛️ @Harvard is the world’s leading institutional contributor, followed by the Chinese Academy of Sciences @CAS__Science and @NIH 🎯 Countries with the strongest cancer research focus relative to their overall scientific output include the 🇺🇸 🇳🇱 🇸🇬 🇨🇦 🇹🇼 .

Development of CAR T therapy and first-in-human individual participant trial for patients with alveolar soft part sarcoma and other MiT/TFE-driven diseases. Spectacular academic initiative - congratulation to F. Zemp and D. Mahoney and their teams. DOI: 10.1038/s43018-026-01194-3

Thrilled to join #JCO as Consultant Editor! Excited to contribute to the journal's important work in disseminating high-quality cancer research @JCO_ASCO @ASCO